Breast Cancer, Oligometastasis
Conditions
Keywords
breast cancer, oligometastasis, radiotherapy, SBRT
Brief summary
Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases. In addition to standard treatments that act on the whole body, such as chemotherapy or hormonal therapy, these patients might also benefit from local treatments that directly target the cancer spots. One of these local treatments is stereotactic body radiotherapy (SBRT), a non-invasive radiation treatment that delivers high doses of radiation in a few sessions. In the past, most of the evidence about the benefit of local treatments came from surgery. More recently, there has been growing interest in SBRT because it does not require surgery. However, the results of studies so far have not been consistent.The goal of this multicenter retrospective study is to better understand whether SBRT can improve disease control and survival in patients with breast cancer that has spread to a limited number of sites outside the brain.
Interventions
None listed
Sponsors
Istituto Clinico Humanitas
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥18 years * Histological diagnosis of breast cancer * Oligometastatic or oligoprogressive metastatic breast cancer * SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition * Ability to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | from January 2010 to December 2023 | years of survival without disease progression assessed by imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local Control | from January 2010 to December 2023 | time between treatment and disease recurrence assessed by imaging |
| overall survival | From January 2010 to December 2023 | the time from diagnosis or initiation of treatment until death from any cause |
| acute and late toxicity RT related | from January 2010 to December 2023 | Evaluation of toxicities related to radiotherapy treatment using the scale CTCAE (Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death) |
Countries
Italy
Contacts
CONTACTRuggero Spoto, MD, Radiation oncologist
CONTACTLaura Bonavita, Master Degree
Outcome results
None listed